JWH 007 is a potent cannabinoid (CB) receptor agonist that avidly binds to both CB1 and CB2 (Ki = 9.5 and 2.9 nM, respectively). This compares favorably with the binding of Δ9-THC, which binds CB1 and CB2 with Ki values of 41 and 36 nM, respectively.
JWH-007 is an analgesic chemical from the naphthoylindole family, which acts as a cannabinoid agonist at both the CB1 and CB2 receptors.
A solution in methanol
DMF: 30 mg/ml
DMSO: 20 mg/ml
Ethanol: 30 mg/ml
219, 320 nm
Storage : -20°C
Shipping : Room Temperature in continental US; may vary elsewhere
Stability : ≥ 1 year
It was first reported in 1994 by a group including the noted cannabinoid chemist John W. Huffman.
It was the most active of the first group of N-alkyl naphoylindoles discovered by the team led by John W Huffman, several years after the family was initially described with the discovery of the N-morpholinylethyl compounds pravadoline (WIN 48,098), JWH-200 (WIN 55,225) and WIN 55,212-2 by the Sterling Winthrop group.
Several other N-alkyl substituents were found to be active by Huffman’s team including the n-butyl, n-hexyl, 2-heptyl, and cyclohexylethyl groups, but it was subsequently determined that the 2-methyl group on the indole ring is not required for CB1 binding, and tends to increase affinity for CB2 instead.
Consequently, the 2-desmethyl derivative of JWH-007, JWH-018, has slightly higher binding affinity for CB1, with an optimum binding of 9.00 nM at CB1 and 2.94 nM at CB2, and JWH-007 displayed optimum binding of 9.50 nM at CB1 and 2.94 nM at CB2.
Another drug similarly named JHW-007 (not JWH) is a cocaine analog (the di-para-fluoro benztropine, being essentially a hybrid between benzatropine and difluoropine; with fluorine groups in the former or being descarbmethoxy in the latter) and atypical dopamine reuptake inhibitor, but is distinct from and not the same as this JWH-007.